SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Rotavirus vaccines in clinical development: Current pipeline and state-of-the-art.

Sartorio, MUA; Folgori, L; Zuccotti, G; Mameli, C (2020) Rotavirus vaccines in clinical development: Current pipeline and state-of-the-art. Pediatr Allergy Immunol, 31 (Suppl 24). pp. 58-60. ISSN 1399-3038 https://doi.org/10.1111/pai.13167
SGUL Authors: Folgori, Laura

[img] Microsoft Word (.docx) Accepted Version
Restricted to Repository staff only until 3 February 2021.
Available under License ["licenses_description_publisher" not defined].

Download (66kB)

Abstract

Rotavirus (RV) disease is a leading cause of mortality and morbidity, especially in children under 5 years of age. The introduction of the two oral rotavirus vaccines Rotarix® and RotaTeq® has shown significant reductions in RV-related mortality, severe RV disease, and hospitalizations. However, some barriers, including a reduced efficacy in low-income countries, safety issues regarding the intussusception risk, age restrictions on vaccine use, the live-attenuated nature itself, and the substantial vaccine costs, currently restrict the full potential of RV disease prevention. Therefore, research is now focusing on the implementation of new oral vaccines and the development of parenteral vaccines to overcome these limits. This review provides an overview of the new rotavirus vaccines in clinical development and the ongoing clinical trials on new RV vaccines in the pediatric age.

Item Type: Article
Additional Information: This is the peer reviewed version of the following article: Sartorio, MUA, Folgori, L, Zuccotti, G, Mameli, C. Rotavirus vaccines in clinical development: Current pipeline and state‐of‐the‐art. Pediatr Allergy Immunol. 2020; 31(Suppl 24): 58–60, which has been published in final form at https://doi.org/10.1111/pai.13167. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.
Keywords: rotavirus, vaccines, 1107 Immunology, 1114 Paediatrics and Reproductive Medicine, Allergy
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Pediatr Allergy Immunol
ISSN: 1399-3038
Language: eng
Dates:
DateEvent
3 February 2020Published
15 October 2019Accepted
Publisher License: Publisher's own licence
PubMed ID: 32017224
Go to PubMed abstract
URI: http://openaccess.sgul.ac.uk/id/eprint/111665
Publisher's version: https://doi.org/10.1111/pai.13167

Actions (login required)

Edit Item Edit Item